GET DAILY SIGNALSBioCryst Pharmaceuticals (BCRX) Delivers Solid Q3 Results and Raises Full-Year Outlook
Key Takeaways
- BioCryst reported third quarter 2026 total revenue of $180.3 million, up from $159.4 million a year earlier, beating the consensus estimate of roughly $165.4 million.
- Diluted earnings per share (EPS) came in at $0.14, above analyst expectations of $0.09, while net income of $37.9 million nearly tripled from $12.9 million in the prior-year quarter.
- ORLADEYO, the company's oral therapy for hereditary angioedema (HAE, a rare condition causing severe swelling), generated $174.8 million in quarterly revenue, up 20% year over year on a comparable basis.
- The company raised its full-year 2026 total revenue guidance to a range of $715 million to $730 million and tightened its non-GAAP operating expense outlook to $415 million to $425 million.
- Non-GAAP operating profit grew about 70% year over year, while cash and investments stood at roughly $376 million at quarter end.
- You can find more information about the ticker's Major News, Today's Price Move, Price Targets, and Forecast on additional pages.
- Explore Trending AI Robots to discover automated trading strategies and market insights.
Earnings Context and Why It Matters
BioCryst Pharmaceuticals is moving from a single-product focus in hereditary angioedema toward a wider rare-disease platform. Its flagship ORLADEYO franchise still drives most revenue and profits, while the pipeline—centered on navenibart from the January 2026 acquisition of Astria Therapeutics—offers the next phase of potential growth. This quarter’s report helps show whether ORLADEYO’s commercial momentum and cost discipline can continue to support that shift. I’m watching the August launch of ORLADEYO pellets for pediatric patients and the move to CareMed as the sole specialty pharmacy partner, both of which could influence demand patterns into 2027.
Reported Results
For the third quarter ended September 30, 2026, BCRX posted total revenue of $180.3 million versus $159.4 million in the same period last year. ORLADEYO accounted for $174.8 million of the total, with licensing and other revenue contributing the remaining $5.5 million. Diluted EPS reached $0.14, ahead of the $0.09 consensus, and revenue also exceeded the roughly $165.4 million Wall Street forecast. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
On a GAAP basis, net income was $37.9 million, up sharply from $12.9 million a year earlier. Non-GAAP operating profit came in near $86 million, roughly 70% higher year over year, while non-GAAP net income more than doubled to $71 million. Cash, equivalents, and investments totaled about $376 million at quarter end.
Management lifted full-year 2026 total revenue guidance to $715 million–$730 million, citing higher licensing revenue and international RAPIVAB orders, while leaving ORLADEYO guidance unchanged at $625 million–$645 million. Non-GAAP operating expense guidance was tightened to $415 million–$425 million.
Market Reaction and Investor Sentiment
BCRX shares rose about 1.7% after the November 4 presentation, closing near $8.72. The market appeared to reward the revenue and EPS beats along with the raised full-year outlook. Stronger profitability and management’s confidence in ongoing revenue growth with a lower cost base into 2027 helped sentiment. At the same time, the quarter included an initial specialty pharmacy inventory build tied to the CareMed transition, which management noted is a one-time factor rather than a recurring trend. Investors are balancing that temporary boost against underlying demand and early signs from the pediatric pellet launch.
Forward Outlook and Key Factors to Monitor
Looking ahead, BioCryst expects revenue to keep growing while operating expenses decline further in 2027 as the full impact of 2026 cost actions takes hold. Formal 2027 guidance has not been issued yet, but the combination of growth and efficiency is expected to support further profit expansion.
The key near-term catalyst remains navenibart, the long-acting injectable HAE candidate whose pivotal trial completed enrollment in June 2026. Top-line data are due in the third quarter of 2027 and will be central to the company’s aim of addressing both oral and injectable HAE patients.
Additional items to follow include early clinical data on BCX17725 for Netherton syndrome, expected before year-end 2026, and progress with the 150 mg ORLADEYO pellet launch for patients ages 12 and older. The CareMed transition and its inventory effects will also warrant attention. Each of these could influence revenue growth and profitability into 2027.
Using AI Tools in My Research Process
When reviewing quarterly results like these, I often turn to Tickeron’s AI Screener to quickly compare BCRX against peers on fundamentals, technical patterns, and recent performance. It helps narrow the field efficiently before diving deeper into company-specific details. The tool has become a regular part of how I cross-check earnings surprises and identify comparable names in the rare-disease space.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
BCRX's RSI Indicator ascends from oversold territory
The RSI Oscillator for BCRX moved out of oversold territory on October 07, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 35 similar instances when the indicator left oversold territory. In 28 of the 35 cases the stock moved higher. This puts the odds of a move higher at 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on BCRX as a result. In 75 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for BCRX just turned positive on October 27, 2026. Looking at past instances where BCRX's MACD turned positive, the stock continued to rise in 39 of 53 cases over the following month. The odds of a continued upward trend are 74%.
Following a +5.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where BCRX advanced for three days, in 202 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 50-day moving average for BCRX moved below the 200-day moving average on October 27, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BCRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
BCRX broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BCRX entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-4.635) is normal, around the industry mean (7.659). P/E Ratio (-6.104) is within average values for comparable stocks, (0.330). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (2.097) is also within normal values, averaging (181.047).
The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. BCRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BCRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of small molecule pharmaceuticals
Industry PharmaceuticalsGeneric
Advertisement